Literature DB >> 12488288

The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era.

K D Miller1, C J Sweeney, G W Sledge.   

Abstract

If your Snark be a Snark, that is right: Fetch it home by all means-you may serve it with greens, And it's handy for striking a light. "But oh, beamish nephew, beware of the day, If your Snark be a Boojum! For then You will softly and suddenly vanish away, And never be met with again!" Lewis Carroll The Hunting of the Snark

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12488288     DOI： 10.1093/annonc/mdg033

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


  10 in total

Review 1.  Tumor angiogenesis.

Authors:  Robert S Kerbel
Journal:  N Engl J Med       Date:  2008-05-08       Impact factor: 91.245

Review 2.  VEGF-targeting therapy for breast cancer.

Authors:  George W Sledge
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-10       Impact factor: 2.673

3.  Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity.

Authors:  Hans Petter Eikesdal; Hikaru Sugimoto; Gabriel Birrane; Yohei Maeshima; Vesselina G Cooke; Mark Kieran; Raghu Kalluri
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-25       Impact factor: 11.205

4.  Angiogenesis inhibition in prostate cancer: current uses and future promises.

Authors:  Jeanny B Aragon-Ching; Ravi A Madan; William L Dahut
Journal:  J Oncol       Date:  2010-02-11       Impact factor: 4.375

5.  VEGF Trap induces antiglioma effect at different stages of disease.

Authors:  Candelaria Gomez-Manzano; Jocelyn Holash; Juan Fueyo; Jing Xu; Charles A Conrad; Kenneth D Aldape; John F de Groot; B Nebiyou Bekele; W K Alfred Yung
Journal:  Neuro Oncol       Date:  2008-08-14       Impact factor: 12.300

Review 6.  Antiangiogenic therapy for metastatic breast cancer: current status and future directions.

Authors:  Arlene Chan
Journal:  Drugs       Date:  2009       Impact factor: 9.546

7.  Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis.

Authors:  Frank Kuhnert; Betty Y Y Tam; Barbara Sennino; John T Gray; Jenny Yuan; Angeline Jocson; Nihar R Nayak; Richard C Mulligan; Donald M McDonald; Calvin J Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-16       Impact factor: 11.205

Review 8.  Drug resistance associated with antiangiogenesis therapy.

Authors:  Hans Petter Eikesdal; Raghu Kalluri
Journal:  Semin Cancer Biol       Date:  2009-06-11       Impact factor: 15.707

9.  Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma.

Authors:  Thi Bich Uyen Le; Thanh Chung Vu; Rebecca Zhi Wen Ho; Aldo Prawira; Lingzhi Wang; Boon Cher Goh; Hung Huynh
Journal:  Int J Mol Sci       Date:  2020-12-10       Impact factor: 5.923

10.  cRGD inhibits vasculogenic mimicry formation by down-regulating uPA expression and reducing EMT in ovarian cancer.

Authors:  Jiao Tang; Jianguo Wang; Lin Fan; Xiaoxuan Li; Na Liu; Wanxian Luo; Jihui Wang; Yifeng Wang; Ying Wang
Journal:  Oncotarget       Date:  2016-04-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.